Silo Pharma inc | Company Profile
OTCQB : SILO
Latest Sector Updates
Silo pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is looking to address conditions such as Fibromyalgia, PTSD, Parkinson’s and other rare neurological disorders which it believes are underserved by current treatments. The company aim to combine their resources with world-class medical research partners to make advances in the medical and psychedelic space.
Stock information
Contact Information
Latest Silo Pharma News
Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammation December 02, 2021 08:10 ETÂ | Source:Â Silo Pharma, Inc. ...
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as ...
Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease
Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has entered into ...
Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner ...
Silo Pharma Advances Psychedelic Patent Portfolio
Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct ...
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO ...
